Amgen finds a new top scientist in Novartis veteran Bradner
BioPharma
Stay updated with breaking news from Jay Bradner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Targeted protein degradation uses different types of "degrading" drugs (degraders) to force proximity between a target protein (for example, a mutated protein that contributes to the development of a disease) and the cellular machinery that directs protein degradation.
This week, the Institute for Research in Biomedicine (IRB Barcelona) and the BBVA Foundation are hosting the 39th Barcelona BioMed Conference—an event in which leading figures can exchange ideas and discuss the latest advances in the field of proximity induction-based pharmacology. The “Proximity-inducing pharmacology: Targeted protein degradation and beyond” conference, co-organised by Dr. Cristina Mayor-Ruiz, from IRB Barcelona, and Dr. Georg E. Winter, from the CeMM Research Center for Molecular Medicine in Vienna (Austria), is being held in Barcelona between 22 and 24 May. Dr. May...
After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of NovartisBuilding on NIBR foundation, Dr. Marshall